Exosomal Biglycan promotes gastric cancer progression via M2 polarization and CXCL10-mediated JAK/STAT1 activation
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Wenchao Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, 528406, China; The Department of Thyroid and…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Biglycan, Chemokine CXCL10, Exosomes. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Recent advancements in tumor immunotherapy have highlighted the importance of the tumor microenvironment in modulating immune responses against cancer cells. Within the TME, macrophages - particularly the M2 phenotype - serve pivotal regulatory functions through cytokine/chemokine secretion to modulate tumor progression. Elucidating the molecular crosstalk between gastric cancer (GC) cells and tumor-associated macrophages (TAMs) remains imperative for developing targeted therapeutic interventions. In this study, we identified Biglycan (BGN), a small leucine-rich proteoglycan, as a key mediator in GC progression. Exosomal BGN derived from GC cell is delivered to macrophages, where it binds to NONO protein, thereby driving M2 polarization and upregulating CXCL10 expression. Elevated CXCL10 levels activate the JAK/STAT1 signaling pathways, thereby potentiating GC cell proliferation, invasion, and metastatic dissemination. Clinically, elevated BGN expression correlates with advanced tumor stage and poor prognosis in GC patients, positioning it as a promising therapeutic target. Our findings reveal a previously unrecognized mechanism of exosomal BGN-mediated M2 macrophage reprogramming and CXCL10-driven oncogenic signaling in the GC microenvironment. These insights establish a novel therapeutic paradigm for GC management through disruption of tumor-macrophage communication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, 528406, China; The Department of Thyroid and Breast Surgery, The Third Affiliated Hospital of Sun Yat-sen Universi…
- Department of General Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, 515063, China.
- Department of Gastric Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510510, China.
- Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, 528406, China.
- Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney at Westmead Hospital, Westmead, NSW, 2145, Australia. Electronic address: liang.qiao@sydney.edu.au.
- Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, 528406, China; Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital o…
Zitieren
APA
Li, W., Wei, H., Liu, J., Zhao, Z., Wang, F., Qiao, L., Yin, S., Zhang, C., & Huo, M. (2025). Exosomal Biglycan promotes gastric cancer progression via M2 polarization and CXCL10-mediated JAK/STAT1 activation. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217758
Vancouver
Li W, Wei H, Liu J, Zhao Z, Wang F, Qiao L, et al. Exosomal Biglycan promotes gastric cancer progression via M2 polarization and CXCL10-mediated JAK/STAT1 activation. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217758
BibTeX
@article{Li2025,
author = {Li, Wenchao and Wei, Hongfa and Liu, Junjie and Zhao, Zidan and Wang, Fuhui and Qiao, Liang and Yin, Songcheng and Zhang, Changhua and Huo, Mingyu},
title = {Exosomal Biglycan promotes gastric cancer progression via M2 polarization and CXCL10-mediated JAK/STAT1 activation},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217758}
}
EUVIMED